GlassScriptPhysician profile
Mark Allen Roemer
NPI 1285663088
$1,722.25
in general payments reported to CMS, 2019-2025
25 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $110 · 2022: $125 · 2023: $210 · 2024: $322 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $256.80 | 2024-2025 | Purified Cortrophin Gel |
| Melinta Therapeutics, LLC | $172.96 | 2019-2020 | |
| Tactile Systems Technology INC | $166.70 | 2019-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Smith+Nephew, INC. | $165.96 | 2019-2024 | Collagenase Santyl, Pico, Renasys Touch |
| Pfizer INC. | $139.02 | 2019 | |
| Horizon Therapeutics Plc | $115.46 | 2022-2023 | Krystexxa |
| Organogenesis INC. | $112.50 | 2019-2024 | Puraply |
| Integra Lifesciences Corporation | $98.93 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Vertex Pharmaceuticals Incorporated | $77.70 | 2025 | |
| Amgen INC. | $72.03 | 2024-2025 | Krystexxa |
| Avita Medical Americas, LLC | $49.08 | 2024 | |
| Convatec INC. | $43.89 | 2023 | |
| Abbvie INC. | $40.90 | 2024 | |
| Kci USA, INC. | $34.60 | 2019 | |
| Medtronic, INC. | $28.11 | 2024 | Intellis Adaptivestim |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $25.72 | 2025 | Activ.A.C. |
| Paratek Pharmaceuticals, INC. | $19.84 | 2025 | Nuzyra |
| Abbott Laboratories | $16.77 | 2019 | |
| Merck Sharp & Dohme LLC | $15.23 | 2019 | |
| Alfasigma USA, INC. | $12.84 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $12.71 | 2019 | |
| Mckesson Patient Care Solutions INC. | $11.57 | 2019 | |
| Sebela Pharmaceuticals INC. | $11.37 | 2020 | |
| Zyla Life Sciences, INC. | $11.32 | 2019 | |
| Normatec Industries, LP | $10.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Roemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.